US and Europe Gene Editing Market is expected to reach US$ 15,052.92 million in 2030

Publisher: The Insight Partners

CRISPR Segment to Grow at Fast CAGR During 2022–2030

According to our new research study on “US and Europe Gene Editing Market Forecast to 2030 – COVID-19 Impact and Regional Analysis by Technology, Product and Services, Application, End User, and Country,” the US and Europe gene editing market size is expected to reach US$ 15,052.92 million in 2030 from US$ 3,955.09 million in 2022; the market is estimated to record a CAGR of 18.2% during 2023–2030. The report highlights trends prevailing in the market, and the factors driving and hindering the US and Europe gene editing market growth.

The growth of the US and Europe gene editing market is attributed to the rise in the prevalence of cancer and other genetic disorders, and continuous technological advancements in gene editing tools. However, the high cost of production of tools required for gene editing methods hinders the market growth.

To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00029986 Based on technology, the US and Europe gene editing market is segmented into CRISPR, TALEN, antisense, Zinc Finger Nucleases (ZFNs), and others. The CRISPR segment held the largest market share in 2022. Moreover, the same segment is estimated to register the highest CAGR during the forecast period. The clustered regularly interspaced short palindromic repeats (CRISPR) are associated with Cas genes that are essential for adaptive immunity in selected bacteria and archaea. CRISPR enables organisms to respond to the changes and eliminate the invading genetic material. Three types of CRISPR mechanisms have been adopted for genome-editing protocols: the wild-type Cas9, the mutated Cas9, and the nuclease-deficient Cas9. CRISPR-Cas9 is faster, cheaper, and more accurate than the other technologies of DNA editing and is used for a wide range of therapeutic applications. It is considered the simplest, most versatile, and precise method of genetic manipulation.

Gene editing tools have been explored to combat COVID-19 in the last few years. In October 2021, researchers from the Georgia Institute of Technology and Emory University developed gene-edited enzymes that attack the polymerase chains of the virus to stop its RNA replication, thereby aiding in patient recovery. This new treatment is also being studied for its administration to the lungs using a nebulizer for better accessibility and easier administration.

Thermo Fisher Scientific Inc.; Merck KGaA; Lonza; PerkinElmer.; Integrated DNA Technologies; GenScript; New England Biolabs; Eurofins Scientific; CRISPR Therapeutics; Editas Medicine; and ElevateBio are among the leading companies operating in the US and Europe gene editing market.

The report segments the US and Europe gene editing market as follows:

Based on technology, the US and Europe gene editing market is segmented into CRISPR, TALEN, antisense, Zinc Finger Nucleases (ZFNs), and others. Based on product and service, the market is segmented into reagents and consumables, instruments, and others. The US and Europe gene editing market, by application, is segmented into cell line engineering, genetic engineering, diagnostic application, drug discovery, and others. In terms of end user, the US and Europe gene editing market is segmented into pharmaceutical & biotechnology companies, academic and research institutes, contract research organizations (CROs), and others. Based on country, the US and Europe gene editing market is segmented into the US and Europe (France, Germany, the UK, Italy, Spain, and the Rest of Europe).

Contact Us
Contact Us: The Insight Partners 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com